Butabarbital

Summary

Butabarbital (CHEMBL449) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 212.25 Da · C10H16N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL449
Name	Butabarbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2479
ChEBI	CHEBI:3228
Molecular formula	C10H16N2O3
Molecular weight	212.25
InChIKey	ZRIHAIZYIMGOAB-UHFFFAOYSA-N

SMILES: CCC(C)C1(C(=O)NC(=O)NC1=O)CC

IUPAC name: 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione

Also known as: Butabarbital, Butabarbital ciii, Butatab, Medarsed, Nilox, Sec-butobarbitone, Secbutabarbital, Unicelles, secbutabarbital, BUTABARBITAL

Parent form; salt/anhydrous children: CHEMBL1200982

Patent coverage: 2,613 distinct patent families (8,803 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,799 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).